IP strategy for cell therapy also has unique challenges. The patent at issue in T 1259/22, although relatively old (expiring August 2024 with SPCs), nonetheless highlights some of the key challenges for cell therapy IP strategy.
At Evolve, we are excited to be involved in protecting the innovative science behind advanced therapies. We recognise that these new modalities have the potential to transform the treatment paradigm for previously incurable diseases. We are passionate about ensuring that IP strategy enables further investment in these ground-breaking scientific and clinical developments. We have extensive experience of crafting and implementing IP strategies for advanced modalities that take account of the complex and unique scientific, commercial and regulatory environment for these highly innovative technologies.
As the former IP lead for the biopharma cell therapy department at AstraZeneca, Evolve’s biotech IP attorney Rose Hughes is ideally placed to assist you with securing robust protection for your cell therapy technologies. At AstraZeneca Rose led the IP strategy for a range of cell therapy programs, including including CAR-T, allogenic/off-the shelf and regenerative cell therapies. Rose also has extensive transactional experience in the cell therapy space, including platform technologies and clinical stage products. .
